A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists

Between 2000 and 2005 several studies revealed that morphine is more potent and exhibits fewer side effects in beta-arrestin 2 knockout mice. These findings spurred efforts to develop opioids that signal primarily via G protein activation and do not, or only very weakly, recruit beta-arrestin. Devel...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Kendall L. Mores, Benjamin R. Cummins, Robert J. Cassell, Richard M. van Rijn
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-04-01
Subjects:	kappa opioid receptor beta-arrestin G protein signaling bias nalfurafine diphenethylamine
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.00407/full